PURPOSE: To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36) delivery. METHODS: PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or solution. RESULTS: Achieved loading degrees were high (12.2 - 16.0% w/w). PYY3-36 release was sustained from all microparticles; order of PYY3-36 release was TOPSi > THCPSi > UnTHCPSi both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and 6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively. Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously in TOPSi, THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release. CONCLUSIONS: PSi represents a promising sustained and tailorable release system for PYY3-36.
PURPOSE: To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36) delivery. METHODS: PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or solution. RESULTS: Achieved loading degrees were high (12.2 - 16.0% w/w). PYY3-36 release was sustained from all microparticles; order of PYY3-36 release was TOPSi > THCPSi > UnTHCPSi both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and 6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively. Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously in TOPSi, THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release. CONCLUSIONS: PSi represents a promising sustained and tailorable release system for PYY3-36.
Authors: Frank H Koegler; Pablo J Enriori; Sonja K Billes; Diana L Takahashi; Meghan S Martin; Randall L Clark; Anne E Evans; Kevin L Grove; Judy L Cameron; Michael A Cowley Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: Prasanth K Chelikani; Alvin C Haver; Joseph R Reeve; David A Keire; Roger D Reidelberger Journal: Am J Physiol Regul Integr Comp Physiol Date: 2005-10-06 Impact factor: 3.619
Authors: Ann Marie Kaukonen; Leena Laitinen; Jarno Salonen; Jaani Tuura; Teemu Heikkilä; Tarja Limnell; Jouni Hirvonen; Vesa-Pekka Lehto Journal: Eur J Pharm Biopharm Date: 2006-12-01 Impact factor: 5.571
Authors: Amy B Foraker; Rob J Walczak; Michael H Cohen; Tony A Boiarski; Carl F Grove; Peter W Swaan Journal: Pharm Res Date: 2003-01 Impact factor: 4.200
Authors: Rachel L Batterham; Michael A Cowley; Caroline J Small; Herbert Herzog; Mark A Cohen; Catherine L Dakin; Alison M Wren; Audrey E Brynes; Malcolm J Low; Mohammad A Ghatei; Roger D Cone; Stephen R Bloom Journal: Nature Date: 2002-08-08 Impact factor: 49.962
Authors: Rachel L Batterham; Mark A Cohen; Sandra M Ellis; Carel W Le Roux; Dominic J Withers; Gary S Frost; Mohammad A Ghatei; Stephen R Bloom Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245